News
2024 Tang Prize Master’s Forum: Contemporary Development of Type-2 Diabetes Treatment and Obesity Control
The Tang Prize is a biennial international award founded by the Taiwanese entrepreneur Samuel Yen-Liang Yin and is the most representative international prize awarded by Taiwan. The 2024 laureates in the field of biopharmaceutical science include Dr. Joel F. Habener, Dr. Svetlana Mojsov, and Dr. Jens Juul Holst, in honor “for the discovery of GLP-1 (7-37) as an insulinotropic factor and the development of GLP-1 (7-37)-based anti-diabetic and anti-obesity drugs.” On October 1st, 2024, CMU is very honored to invite Dr. Svetlana Mojsov and Dr. Jens Juul Holst to attend the 2024 Tang Prize Master’s Forum co-organized by CMU and Tang Prize Foundation.
During the forum, Dr. Svetlana Mojsov gave a keynote speech on the topic of “Chemistry Matters: From A Putative Peptide to Efficient Therapeutics for Diabetes and Obesity” and Dr. Jens Juul Holst gave a keynote speech on the topic of “Incretin hormones as a basis for treatment of obesity”. They explained how they discovered GLP-1(7-37), the difficulties they encountered during the research, and how they overcame the difficulties to develop GLP-1(7-37) into a drug for treating diabetes and controlling obesity.
After the keynote speech, the panelists were invited to discuss about the significant contribution and forward-looking development of GLP-1(7-37) to the treatment of diabetes and weight loss. The forum was held in a hybrid format, both on-site and online participation was opened, allowing more scholars to attend and interact. The 2024 Tang Prize Masters Forum was a huge success, and the attending scholars, teachers, and students all benefited a lot.
【Photos】
|
